Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Am J Hum Genet ; 108(2): 284-294, 2021 02 04.
Article in English | MEDLINE | ID: mdl-33421400

ABSTRACT

Mastocytosis is a rare myeloid neoplasm characterized by uncontrolled expansion of mast cells, driven in >80% of affected individuals by acquisition of the KIT D816V mutation. To explore the hypothesis that inherited variation predisposes to mastocytosis, we performed a two-stage genome-wide association study, analyzing 1,035 individuals with KIT D816V positive disease and 17,960 healthy control individuals from five European populations. After quality control, we tested 592,007 SNPs at stage 1 and 75 SNPs at stage 2 for association by using logistic regression and performed a fixed effects meta-analysis to combine evidence across the two stages. From the meta-analysis, we identified three intergenic SNPs associated with mastocytosis that achieved genome-wide significance without heterogeneity between cohorts: rs4616402 (pmeta = 1.37 × 10-15, OR = 1.52), rs4662380 (pmeta = 2.11 × 10-12, OR = 1.46), and rs13077541 (pmeta = 2.10 × 10-9, OR = 1.33). Expression quantitative trait analyses demonstrated that rs4616402 is associated with the expression of CEBPA (peQTL = 2.3 × 10-14), a gene encoding a transcription factor known to play a critical role in myelopoiesis. The role of the other two SNPs is less clear: rs4662380 is associated with expression of the long non-coding RNA gene TEX41 (peQTL = 2.55 × 10-11), whereas rs13077541 is associated with the expression of TBL1XR1, which encodes transducin (ß)-like 1 X-linked receptor 1 (peQTL = 5.70 × 10-8). In individuals with available data and non-advanced disease, rs4616402 was associated with age at presentation (p = 0.009; beta = 4.41; n = 422). Additional focused analysis identified suggestive associations between mastocytosis and genetic variation at TERT, TPSAB1/TPSB2, and IL13. These findings demonstrate that multiple germline variants predispose to KIT D816V positive mastocytosis and provide novel avenues for functional investigation.


Subject(s)
Genetic Predisposition to Disease , Genome-Wide Association Study , Mastocytosis/genetics , Polymorphism, Single Nucleotide , Proto-Oncogene Proteins c-kit/genetics , Amino Acid Transport System y+/genetics , CCAAT-Enhancer-Binding Proteins/genetics , DNA, Intergenic , Female , Humans , Interleukin-13/genetics , Introns , Male , RNA, Long Noncoding/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Repressor Proteins/genetics , Telomerase/genetics , Tryptases/genetics
2.
Eur J Hum Genet ; 29(4): 593-603, 2021 04.
Article in English | MEDLINE | ID: mdl-33223528

ABSTRACT

ABL1 is a proto-oncogene encoding a nonreceptor tyrosine kinase, best known in the somatic BCR-ABL fusion gene associated with chronic myeloid leukaemia. Recently, germline missense variants in ABL1 have been found to cause an autosomal dominant developmental syndrome with congenital heart disease, skeletal malformations and characteristic facies. Here, we describe a series of six new unrelated individuals with heterozygous missense variants in ABL1 (including four novel variants) identified via whole exome sequencing. All the affected individuals in this series recapitulate the phenotype of the ABL1 developmental syndrome and additionally we affirm that hearing impairment is a common feature of the condition. Four of the variants cluster in the myristoyl-binding pocket of ABL1, a region critical for auto-inhibitory regulation of the kinase domain. Bio-informatic analysis of transcript-wide conservation and germline/somatic variation reveals that this pocket region is subject to high missense constraint and evolutionary conservation. Functional work to investigate ABL1 kinase activity in vitro by transient transfection of HEK293T cells with variant ABL1 plasmid constructs revealed increased phosphorylation of ABL1-specific substrates compared to wild-type. The increased tyrosine kinase activity was suppressed by imatinib treatment. This case series of six new patients with germline heterozygous ABL1 missense variants further delineates the phenotypic spectrum of this condition and recognises microcephaly as a common finding. Our analysis supports an ABL1 gain-of-function mechanism due to loss of auto-inhibition, and demonstrates the potential for pharmacological inhibition using imatinib.


Subject(s)
Foot Deformities/genetics , Hand Deformities/genetics , Hearing Loss/genetics , Heart Defects, Congenital/genetics , Proto-Oncogene Proteins c-abl/genetics , Adolescent , Adult , Binding Sites , Child , Child, Preschool , Female , Foot Deformities/pathology , HEK293 Cells , Hand Deformities/pathology , Hearing Loss/pathology , Heart Defects, Congenital/pathology , Humans , Male , Mutation, Missense , Myristic Acid/metabolism , Phenotype , Protein Binding , Proto-Oncogene Proteins c-abl/chemistry , Proto-Oncogene Proteins c-abl/metabolism , Syndrome
3.
Cells ; 9(7)2020 07 08.
Article in English | MEDLINE | ID: mdl-32650416

ABSTRACT

Our understanding of the significance of epigenetic dysregulation in the pathogenesis of myeloid malignancies has greatly advanced in the past decade. Enhancer of Zeste Homolog 2 (EZH2) is the catalytic core component of the Polycomb Repressive Complex 2 (PRC2), which is responsible for gene silencing through trimethylation of H3K27. EZH2 dysregulation is highly tumorigenic and has been observed in various cancers, with EZH2 acting as an oncogene or a tumor-suppressor depending on cellular context. While loss-of-function mutations of EZH2 frequently affect patients with myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndrome and myelofibrosis, cases of chronic myeloid leukemia (CML) seem to be largely characterized by EZH2 overexpression. A variety of other factors frequently aberrant in myeloid leukemia can affect PRC2 function and disease pathogenesis, including Additional Sex Combs Like 1 (ASXL1) and splicing gene mutations. As the genetic background of myeloid malignancies is largely heterogeneous, it is not surprising that EZH2 mutations act in conjunction with other aberrations. Since EZH2 mutations are considered to be early events in disease pathogenesis, they are of therapeutic interest to researchers, though targeting of EZH2 loss-of-function does present unique challenges. Preliminary research indicates that combined tyrosine kinase inhibitor (TKI) and EZH2 inhibitor therapy may provide a strategy to eliminate the residual disease burden in CML to allow patients to remain in treatment-free remission.


Subject(s)
Enhancer of Zeste Homolog 2 Protein/metabolism , Myeloproliferative Disorders/metabolism , Animals , Enhancer of Zeste Homolog 2 Protein/genetics , Humans , Mutation/genetics , Myeloproliferative Disorders/genetics , Polycomb Repressive Complex 2/genetics , Polycomb Repressive Complex 2/metabolism , Repressor Proteins/genetics , Repressor Proteins/metabolism
4.
Leukemia ; 34(12): 3206-3214, 2020 12.
Article in English | MEDLINE | ID: mdl-32322039

ABSTRACT

EZH2, a component of the polycomb repressive complex 2, catalyses the trimethylation of histone H3 lysine 27, a chromatin mark associated with transcriptional repression. EZH2 loss-of-function mutations are seen in myeloid neoplasms and are associated with an adverse prognosis. Missense mutations in the SET/CXC domain abrogate catalytic activity as assessed by in vitro histone methylation assays, but missense mutations clustering in the conserved DI and DII regions retain activity. To understand the role of DI and DII mutations, we initially developed a cell-based histone methylation assay to test activity in a cellular context. Murine induced pluripotent stem cells lacking EZH2 were transiently transfected with wild type or mutant EZH2 (n = 15) and any resulting histone methylation was measured by flow cytometry. All DI mutations (n = 5) resulted in complete or partial loss of methylation activity whilst 5/6 DII mutations retained activity. Next, we assessed the possibility of splicing abnormalities induced by exon 8 mutations (encoding DII) using RT-PCR from primary patient samples and mini-gene assays. Exon 8 mutations resulted in skipping of exon 8 and an out-of-frame transcript. We have therefore shown that mutations within regions encoding EZH2 domains DI and DII are pathogenic by loss of function and exon skipping, respectively.


Subject(s)
Enhancer of Zeste Homolog 2 Protein/genetics , Mutation/genetics , Myeloproliferative Disorders/genetics , Animals , Cell Line , Histones/genetics , Humans , Lysine/genetics , Mice
5.
Leukemia ; 33(2): 415-425, 2019 02.
Article in English | MEDLINE | ID: mdl-30573779

ABSTRACT

Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a diagnostic challenge in many cases. We identified STAT5B N642H, an established oncogenic mutation, in 27/1715 (1.6%) cases referred for investigation of eosinophilia. Of the 27 mutated cases, a working diagnosis of hypereosinophilic syndrome (HES; n = 7) or a myeloid neoplasm with eosinophilia (n = 20) had been made prior to the detection of STAT5B N642H. Myeloid panel analysis identified a median of 2 additional mutated genes (range 0-4) with 4 cases having STAT5B N642H as a sole abnormality. STAT5B N642H was absent in cultured T cells of 4/4 positive cases. Individuals with SF3B1 mutations (9/27; 33%) or STAT5B N642H as a sole abnormality had a markedly better overall survival compared to cases with other additional mutations (median 65 months vs. 14 months; hazard ratio = 8.1; P < 0.001). The overall survival of STAT5B-mutated HES cases was only 30 months, suggesting that these cases should be reclassified as chronic eosinophilic leukemia, not otherwise specified (CEL-NOS). The finding of STAT5B N642H as a recurrent mutation in myeloid neoplasia with eosinophilia provides a new diagnostic and prognostic marker as well as a potential target for therapy.


Subject(s)
Biomarkers, Tumor/genetics , Eosinophilia/genetics , Mutation , Myeloproliferative Disorders/genetics , STAT5 Transcription Factor/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Child , Eosinophilia/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myeloproliferative Disorders/pathology , Prognosis , Retrospective Studies , Survival Rate , Young Adult
6.
Leukemia ; 33(5): 1184-1194, 2019 05.
Article in English | MEDLINE | ID: mdl-30573780

ABSTRACT

Acquired uniparental disomy (aUPD, also known as copy-neutral loss of heterozygosity) is a common feature of cancer cells and characterized by extended tracts of somatically-acquired homozygosity without any concurrent loss or gain of genetic material. The presumed genetic targets of many regions of aUPD remain unknown. Here we describe the association of chromosome 22 aUPD with mutations that delete the C-terminus of PRR14L in patients with chronic myelomonocytic leukemia (CMML), related myeloid neoplasms and age-related clonal hematopoiesis (ARCH). Myeloid panel analysis identified a median of three additional mutated genes (range 1-6) in cases with a myeloid neoplasm (n = 8), but no additional mutations in cases with ARCH (n = 2) suggesting that mutated PRR14L alone may be sufficient to drive clonality. PRR14L has very limited homology to other proteins and its function is unknown. ShRNA knockdown of PRR14L in human CD34+ cells followed by in vitro growth and differentiation assays showed an increase in monocytes and decrease in neutrophils, consistent with a CMML-like phenotype. RNA-Seq and cellular localization studies suggest a role for PRR14L in cell division. PRR14L is thus a novel, biallelically mutated gene and potential founding abnormality in myeloid neoplasms.


Subject(s)
Chromosomal Proteins, Non-Histone/genetics , Chromosomes, Human, Pair 22 , Hematopoiesis/genetics , Mutation , Myeloproliferative Disorders/genetics , Uniparental Disomy , Cell Differentiation/genetics , Female , Fluorescent Antibody Technique , Gene Expression Regulation, Leukemic , Gene Knockdown Techniques , Gene Knockout Techniques , Humans , Male , Myeloproliferative Disorders/diagnosis , Phenotype , Polymorphism, Single Nucleotide , Exome Sequencing
8.
Nat Commun ; 6: 6691, 2015 Apr 07.
Article in English | MEDLINE | ID: mdl-25849990

ABSTRACT

Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,083 controls, we identify two SNPs with genome-wide significance in JAK2(V617F)-negative MPN: rs12339666 (JAK2; meta-analysis P=1.27 × 10(-10)) and rs2201862 (MECOM; meta-analysis P=1.96 × 10(-9)). Two additional SNPs, rs2736100 (TERT) and rs9376092 (HBS1L/MYB), achieve genome-wide significance when including JAK2(V617F)-positive cases. rs9376092 has a stronger effect in JAK2(V617F)-negative cases with CALR and/or MPL mutations (Breslow-Day P=4.5 × 10(-7)), whereas in JAK2(V617F)-positive cases rs9376092 associates with essential thrombocythemia (ET) rather than polycythemia vera (allelic χ(2) P=7.3 × 10(-7)). Reduced MYB expression, previously linked to development of an ET-like disease in model systems, associates with rs9376092 in normal myeloid cells. These findings demonstrate that multiple germline variants predispose to MPN and link constitutional differences in MYB expression to disease phenotype.


Subject(s)
Polycythemia Vera/genetics , Thrombocythemia, Essential/genetics , Adult , Aged , Alleles , Calreticulin/genetics , Case-Control Studies , Cohort Studies , DNA-Binding Proteins/genetics , Female , GTP-Binding Proteins/genetics , Gene Frequency , Genes, myb/genetics , Genetic Predisposition to Disease , Genetic Variation , Genotype , HSP70 Heat-Shock Proteins/genetics , Humans , Janus Kinase 2/genetics , MDS1 and EVI1 Complex Locus Protein , Male , Middle Aged , Mutation , Myeloproliferative Disorders/genetics , Peptide Elongation Factors/genetics , Polymorphism, Single Nucleotide , Proto-Oncogenes/genetics , Receptors, Thrombopoietin/genetics , Telomerase/genetics , Transcription Factors/genetics
9.
Ann Hematol ; 94(2): 233-8, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25260694

ABSTRACT

Rearrangements of chromosome band 9p24 are known to be associated with JAK2 fusion genes, e.g., t(8;9)(p22;p24) with a PCM1-JAK2 and t(9;22)(p24;q11) with a BCR-JAK2 fusion gene, respectively. In association with myeloid neoplasms, the clinical course is aggressive, and in absence of effective conventional treatment options, long-term remission is usually only observed after allogeneic stem cell transplantation (ASCT). With the discovery of inhibitors of the JAK2 tyrosine kinase and based on encouraging in vitro and in vivo data, we treated two male patients with myeloid neoplasms and a PCM1-JAK2 or a BCR-JAK2 fusion gene, respectively, with the JAK1/JAK2 inhibitor ruxolitinib. After 12 months of treatment, both patients achieved a complete clinical, hematologic, and cytogenetic response. Non-hematologic toxicity was only grade 1 while no hematologic toxicity was observed. However, remission in both patients was only short-term, with relapse occurring after 18 and 24 months, respectively, making ASCT indispensable in both cases. This data highlight (1) the ongoing importance of cytogenetic analysis for the diagnostic work-up of myeloid neoplasms as it may guide targeted therapy and (2) remission under ruxolitinib may only be short-termed in JAK2 fusion genes but it may be an important bridging therapy prior to ASCT.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Oncogene Proteins, Fusion/genetics , Pyrazoles/therapeutic use , Amino Acid Sequence , Base Sequence , DNA Mutational Analysis , Humans , In Situ Hybridization, Fluorescence , Janus Kinases/antagonists & inhibitors , Male , Molecular Sequence Data , Neoplasm Recurrence, Local , Nitriles , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-bcr/genetics , Pyrimidines , Remission Induction , Time Factors
10.
Leuk Res ; 39(1): 82-7, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25499808

ABSTRACT

The recent discovery of somatically acquired CALR mutations in a substantial proportion of patients with myeloproliferative neoplasms has provided a new marker of clonal disease, advancing both diagnosis and prognosis in these previously difficult to characterise disorders. The mutations, which can be challenging to detect on a routine basis, are heterogeneous insertions/deletions (indels) in exon 9 with mutant allele burden that vary substantially between patients. We evaluated four genetic screening methods for their ability to detect a series of different CALR mutations; Sanger sequencing, fragment analysis PCR, high resolution melt (HRM) and targeted next generation sequencing (NGS). The limit of detection (LoD) of each assay was tested using serial dilution series made with DNA from CALR positive sample DNA and a cell line, MARIMO, found to carry a heterozygous 61 nucleotide CALR deletion. All methods were capable of detecting each mutation; HRM and fragment analysis PCR were better at detecting low mutation levels compared to Sanger sequencing but targeted NGS had the lowest LoD at a 1% mutation burden.


Subject(s)
Alleles , Calreticulin/genetics , Hematologic Neoplasms/genetics , Mutation , Myeloproliferative Disorders/genetics , Neoplasm Proteins/genetics , DNA Mutational Analysis/methods , DNA, Neoplasm/genetics , Female , Humans , Lod Score , Male
11.
Haematologica ; 98(1): 103-6, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22875613

ABSTRACT

The 8p11 myeloproliferative syndrome is a rare, aggressive myeloproliferative neoplasm characterized by constitutively active FGFR1 fusion proteins that arise from specific chromosomal translocations and which drive aberrant proliferation. Although FGFR1 inhibitors have shown in vitro activity against FGFR1 fusions, none are in use clinically and there is a need to assess additional compounds as potential therapy. Here we use cell lines and primary cells to investigate ponatinib (AP24534). Ponatinib-treated Ba/F3 cells transformed by ZMYM2-FGFR1 and BCR-FGFR1 and the FGFR1OP2-FGFR1 positive KG1A cell line showed reduced proliferation and decreased survival when compared to control cells. Inhibition induced apoptosis and reduced phosphorylation of the FGFR1 fusion proteins and substrates. Ponatinib-treated cells from 8p11 myeloproliferative syndrome patients (n=5) showed reduced colony growth compared to controls. In one evaluable patient, ponatinib specifically reduced numbers of FGFR1-fusion gene positive colonies. Ponatinib, therefore, shows considerable promise for the treatment of patients with 8p11 myeloproliferative syndrome.


Subject(s)
Imidazoles/administration & dosage , Molecular Targeted Therapy/methods , Myeloproliferative Disorders/drug therapy , Pyridazines/administration & dosage , Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors , Aged , Cell Line, Transformed , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Myeloproliferative Disorders/genetics , Myeloproliferative Disorders/pathology , Receptor, Fibroblast Growth Factor, Type 1/genetics , Receptor, Fibroblast Growth Factor, Type 1/metabolism
12.
Haematologica ; 98(3): 404-8, 2013 Mar.
Article in English | MEDLINE | ID: mdl-22875628

ABSTRACT

JAK2 fusion genes are rare but recurrent abnormalities associated with diverse, clinically heterogeneous hematologic malignancies. Here we assess the JAK1/2 inhibitor ruxolitinib as therapy for patients with JAK2-rearrangement associated myeloproliferative neoplasms (MPN). Ruxolitinib-treated Ba/F3 cells transformed to IL3 independence by ETV6-JAK2 showed reduced proliferation and survival (IC(50) = 370 nM) compared with KG1A or Ba/F3 cells transformed by BCR-ABL1, SPBN1-FLT3 and ZMYM2-FGFR1 (IC(50) > 10 µM for all). Inhibition was associated with reduced phosphorylation of ETV6-JAK2, ERK, STAT5 and AKT. Primary cell growth from 2 patients with JAK2 rearrangement and one patient with JAK2 amplification was assessed in methylcellulose assays. Reduced colony growth was seen for all patients in ruxolitinib-treated cultures compared with healthy controls (n=7). Fluorescence in situ hybridization showed reduced growth of JAK2-rearrangement positive colonies compared to JAK2-rearrangement negative colonies. Our data, therefore, provide evidence that ruxolitinib is a promising therapy for treatment of patients with JAK2 fusion genes.


Subject(s)
Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/genetics , Protein Kinase Inhibitors/pharmacology , Pyrazoles/pharmacology , Recombination, Genetic , Aged , Cell Line, Tumor , Gene Amplification , Humans , Male , Middle Aged , Molecular Targeted Therapy , Myeloproliferative Disorders/diagnosis , Myeloproliferative Disorders/drug therapy , Myeloproliferative Disorders/genetics , Nitriles , Oncogene Proteins, Fusion/genetics , Oncogene Proteins, Fusion/metabolism , Protein Kinase Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Pyrimidines , Translocation, Genetic
13.
Nat Genet ; 45(1): 18-24, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23222956

ABSTRACT

Atypical chronic myeloid leukemia (aCML) shares clinical and laboratory features with CML, but it lacks the BCR-ABL1 fusion. We performed exome sequencing of eight aCMLs and identified somatic alterations of SETBP1 (encoding a p.Gly870Ser alteration) in two cases. Targeted resequencing of 70 aCMLs, 574 diverse hematological malignancies and 344 cancer cell lines identified SETBP1 mutations in 24 cases, including 17 of 70 aCMLs (24.3%; 95% confidence interval (CI) = 16-35%). Most mutations (92%) were located between codons 858 and 871 and were identical to changes seen in individuals with Schinzel-Giedion syndrome. Individuals with mutations had higher white blood cell counts (P = 0.008) and worse prognosis (P = 0.01). The p.Gly870Ser alteration abrogated a site for ubiquitination, and cells exogenously expressing this mutant exhibited higher amounts of SETBP1 and SET protein, lower PP2A activity and higher proliferation rates relative to those expressing the wild-type protein. In summary, mutated SETBP1 represents a newly discovered oncogene present in aCML and closely related diseases.


Subject(s)
Carrier Proteins/genetics , Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/genetics , Mutation , Nuclear Proteins/genetics , Amino Acid Motifs , Amino Acid Sequence , Amino Acid Substitution , Carrier Proteins/metabolism , DNA-Binding Proteins , Exome , Histone Chaperones/genetics , Histone Chaperones/metabolism , Humans , Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/mortality , Molecular Sequence Data , Nuclear Proteins/metabolism , Prognosis , Protein Binding , Protein Interaction Domains and Motifs , Protein Phosphatase 2/metabolism , Sequence Analysis, DNA , Transcription Factors/genetics , Transcription Factors/metabolism
14.
Blood ; 119(5): 1208-13, 2012 Feb 02.
Article in English | MEDLINE | ID: mdl-22053108

ABSTRACT

The polycomb repressive complex 2 (PRC2) is a highly conserved histone H3 lysine 27 methyltransferase that regulates the expression of developmental genes. Inactivating mutations of the catalytic component of PRC2, EZH2, are seen in myeloid disorders. We reasoned that the other 2 core PRC2 components, SUZ12 and EED, may also be mutational targets in these diseases, as well as associated factors such as JARID2. SUZ12 mutations were identified in 1 of 2 patients with myelodysplastic syndrome/myeloproliferative neoplasms with 17q acquired uniparental disomy and in 2 of 2 myelofibrosis cases with focal 17q11 deletions. All 3 were missense mutations affecting the highly conserved VEFS domain. Analysis of a further 146 myelodysplastic syndrome/myeloproliferative neoplasm patients revealed an additional VEFS domain mutant, yielding a total mutation frequency of 1.4% (2 of 148). We did not find mutations of JARID2 or EED in association with acquired uniparental disomy for chromosome 6p or 11q, respectively; however, screening unselected cases identified missense mutations in EED (1 of 148; 1%) and JARID2 (3 of 148; 2%). All 3 SUZ12 mutations tested and the EED mutation reduced PRC2 histone methyltransferase activity in vitro, demonstrating that PRC2 function may be compromised in myeloid disorders by mutation of distinct genes.


Subject(s)
Bone Marrow Neoplasms/genetics , Gene Silencing , Myelodysplastic-Myeloproliferative Diseases/genetics , Myeloproliferative Disorders/genetics , Repressor Proteins/genetics , Aged , Aged, 80 and over , Amino Acid Sequence , Cohort Studies , DNA Mutational Analysis , Female , Gene Silencing/physiology , Humans , Male , Middle Aged , Molecular Sequence Data , Polycomb-Group Proteins , Sequence Homology, Amino Acid
15.
Clin Cancer Res ; 17(9): 2613-8, 2011 May 01.
Article in English | MEDLINE | ID: mdl-21367748

ABSTRACT

Control of gene expression is exerted at a number of different levels, one of which is the accessibility of genes and their controlling elements to the transcriptional machinery. Accessibility is dictated broadly by the degree of chromatin compaction, which is influenced in part by polycomb group proteins. EZH2, together with SUZ12 and EED, forms the polycomb repressive complex 2 (PRC2), which catalyzes trimethylation of histone H3 lysine 27 (H3K27me3). PRC2 may recruit other polycomb complexes, DNA methyltransferases, and histone deacetylases, resulting in additional transcriptional repressive marks and chromatin compaction at key developmental loci. Overexpression of EZH2 is a marker of advanced and metastatic disease in many solid tumors, including prostate and breast cancer. Mutation of EZH2 Y641 is described in lymphoma and results in enhanced activity, whereas inactivating mutations are seen in poor prognosis myeloid neoplasms. No histone demethylating agents are currently available for treatment of patients, but 3-deazaneplanocin (DZNep) reduces EZH2 levels and H3K27 trimethylation, resulting in reduced cell proliferation in breast and prostate cancer cells in vitro. Furthermore, synergistic effects are seen for combined treatment with DNA demethylating agents and histone deacetylation inhibitors, opening up the possibility of refined epigenetic treatments in the future.


Subject(s)
DNA-Binding Proteins/genetics , Mutation , Neoplasms/genetics , Transcription Factors/genetics , DNA-Binding Proteins/metabolism , Enhancer of Zeste Homolog 2 Protein , Gene Expression Regulation, Neoplastic , Humans , Models, Biological , Mutation/physiology , Polycomb Repressive Complex 2 , Transcription Factors/metabolism
16.
Nat Genet ; 42(8): 722-6, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20601953

ABSTRACT

Abnormalities of chromosome 7q are common in myeloid malignancies, but no specific target genes have yet been identified. Here, we describe the finding of homozygous EZH2 mutations in 9 of 12 individuals with 7q acquired uniparental disomy. Screening of a total of 614 individuals with myeloid disorders revealed 49 monoallelic or biallelic EZH2 mutations in 42 individuals; the mutations were found most commonly in those with myelodysplastic/myeloproliferative neoplasms (27 out of 219 individuals, or 12%) and in those with myelofibrosis (4 out of 30 individuals, or 13%). EZH2 encodes the catalytic subunit of the polycomb repressive complex 2 (PRC2), a highly conserved histone H3 lysine 27 (H3K27) methyltransferase that influences stem cell renewal by epigenetic repression of genes involved in cell fate decisions. EZH2 has oncogenic activity, and its overexpression has previously been causally linked to differentiation blocks in epithelial tumors. Notably, the mutations we identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.


Subject(s)
Genes, Regulator , Cell Differentiation/genetics , DNA-Binding Proteins , Enhancer of Zeste Homolog 2 Protein , Female , Genes, Tumor Suppressor , Histone Methyltransferases , Histone-Lysine N-Methyltransferase , Histones/genetics , Humans , Lysine/genetics , Male , Polycomb Repressive Complex 2 , Proteins/genetics , Transcription Factors
17.
Haematologica ; 95(9): 1473-80, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20421268

ABSTRACT

BACKGROUND: Aberrant activation of tyrosine kinases, caused by either mutation or gene fusion, is of major importance for the development of many hematologic malignancies, particularly myeloproliferative neoplasms. We hypothesized that hitherto unrecognized, cytogenetically cryptic tyrosine kinase fusions may be common in non-classical or atypical myeloproliferative neoplasms and related myelodysplastic/myeloproliferative neoplasms. DESIGN AND METHODS: To detect genomic copy number changes associated with such fusions, we performed a systematic search in 68 patients using custom designed, targeted, high-resolution array comparative genomic hybridization. Arrays contained 44,000 oligonucleotide probes that targeted 500 genes including all 90 tyrosine kinases plus downstream tyrosine kinase signaling components, other translocation targets, transcription factors, and other factors known to be important for myelopoiesis. RESULTS: No abnormalities involving tyrosine kinases were detected; however, nine cytogenetically cryptic copy number imbalances were detected in seven patients, including hemizygous deletions of RUNX1 or CEBPA in two cases with atypical chronic myeloid leukemia. Mutation analysis of the remaining alleles revealed non-mutated RUNX1 and a frameshift insertion within CEBPA. A further mutation screen of 187 patients with myelodysplastic/myeloproliferative neoplasms identified RUNX1 mutations in 27 (14%) and CEBPA mutations in seven (4%) patients. Analysis of other transcription factors known to be frequently mutated in acute myeloid leukemia revealed NPM1 mutations in six (3%) and WT1 mutations in two (1%) patients with myelodysplastic/myeloproliferative neoplasms. Univariate analysis indicated that patients with mutations had a shorter overall survival (28 versus 44 months, P=0.019) compared with patients without mutations, with the prognosis for cases with CEBPA, NPM1 or WT1 mutations being particularly poor. CONCLUSIONS: We conclude that mutations of transcription and other nuclear factors are frequent in myelodysplastic/myeloproliferative neoplasms and are generally mutually exclusive. CEBPA, NPM1 or WT1 mutations may be associated with a poor prognosis, an observation that will need to be confirmed by detailed prospective studies.


Subject(s)
Mutation , Myelodysplastic Syndromes/genetics , Myeloproliferative Disorders/genetics , Transcription Factors/genetics , CCAAT-Enhancer-Binding Proteins/genetics , Comparative Genomic Hybridization , DNA Mutational Analysis , Gene Dosage , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive , Myelopoiesis/genetics , Nuclear Proteins/genetics , Nucleophosmin , Prognosis , WT1 Proteins/genetics
18.
Blood ; 115(22): 4517-23, 2010 Jun 03.
Article in English | MEDLINE | ID: mdl-20304805

ABSTRACT

The 46/1 JAK2 haplotype predisposes to V617F-positive myeloproliferative neoplasms, but the underlying mechanism is obscure. We analyzed essential thrombocythemia patients entered into the PT-1 studies and, as expected, found that 46/1 was overrepresented in V617F-positive cases (n = 404) versus controls (n = 1492, P = 3.9 x 10(-11)). The 46/1 haplotype was also overrepresented in cases without V617F (n = 347, P = .009), with an excess seen for both MPL exon 10 mutated and V617F, MPL exon 10 nonmutated cases. Analysis of further MPL-positive, V617F-negative cases confirmed an excess of 46/1 (n = 176, P = .002), but no association between MPL mutations and MPL haplotype was seen. An excess of 46/1 was also seen in JAK2 exon 12 mutated cases (n = 69, P = .002), and these mutations preferentially arose on the 46/1 chromosome (P = .029). No association between 46/1 and clinical or laboratory features was seen in the PT-1 cohort either with or without V617F. The excess of 46/1 in JAK2 exon 12 cases is compatible with both the "hypermutability" and "fertile ground" hypotheses, but the excess in MPL-mutated cases argues against the former. No difference in sequence, splicing, or expression of JAK2 was found on 46/1 compared with other haplotypes, suggesting that any functional difference of JAK2 on 46/1, if it exists, must be relatively subtle.


Subject(s)
Janus Kinase 2/genetics , Mutation , Myeloproliferative Disorders/genetics , Receptors, Thrombopoietin/genetics , Adult , Aged , Amino Acid Substitution , Base Sequence , Case-Control Studies , Cohort Studies , DNA Primers/genetics , Exons , Female , Gene Frequency , Genetic Predisposition to Disease , Haplotypes , Humans , Linkage Disequilibrium , Male , Middle Aged , Models, Genetic , Mutation, Missense , Polycythemia Vera/genetics , Polymorphism, Single Nucleotide , Prospective Studies , Thrombocythemia, Essential/drug therapy , Thrombocythemia, Essential/genetics
19.
Haematologica ; 95(1): 148-52, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20065083

ABSTRACT

Interferon alpha (IFN) induces variable responses in chronic myeloid leukemia (CML), with 8-30% of early chronic phase cases achieving a complete cytogenetic response. We hypothesized that polymorphic differences in genes encoding IFN signal transduction components might account for different patient responses. We studied 174 IFN-treated patients, of whom 79 achieved less than 35% Philadelphia-chromosome (Ph) positive metaphases (responders) and 95 failed to show any cytogenetic response (more than 95% Ph-positive metaphases; non-responders). We compared 17 single nucleotide polymorphisms (SNPs) at IFNAR1, IFNAR2, JAK1, TYK2, STAT1, STAT3 and STAT5a/b between the two groups and found a significant difference for rs6503691, a SNP tightly linked to STAT5a, STAT5b and STAT3 (minor allele frequency 0.16 for non-responders; 0.06 for responders, P=0.007). Levels of STAT3 mRNA correlated with rs6503691 genotype (P<0.001) as assessed by real time quantitative PCR and therefore we conclude that rs6503691 is associated with the STAT3 expression levels and response of CML patients to IFN.


Subject(s)
Gene Expression Regulation, Neoplastic , Interferon-alpha/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Polymorphism, Single Nucleotide/genetics , STAT3 Transcription Factor/biosynthesis , Adolescent , Adult , Aged , Aged, 80 and over , Child , Drug Resistance, Neoplasm/genetics , Female , Humans , Male , Middle Aged , STAT3 Transcription Factor/genetics , Signal Transduction/genetics , Young Adult
20.
Br J Haematol ; 148(2): 268-73, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20085582

ABSTRACT

We identified four patients who presented with BCR-ABL1 negative myeloproliferative neoplasms and cytogenetically visible abnormalities of chromosome band 5q31-35. Fluorescence in situ hybridization indicated that the platelet-derived growth factor receptor beta gene (PDGFRB) was disrupted in all four cases and 5' rapid amplification of cDNA ends identified in-frame mRNA fusions between PDGFRB and WDR48 (3p21), GOLGA4 (3p21) and BIN2 (12q13). Strikingly, all three genes encode proteins involving intracellular trafficking. Imatinib, a known inhibitor of PDGFRbeta, selectively blocked the growth of t(3;5) myeloid colonies and produced clinically significant responses in all patients. We conclude that PDGFRB fuses to diverse partner genes in atypical myeloproliferative neoplasms (MPNs). Although very rare, identification of these fusions is critical for proper management of affected individuals.


Subject(s)
Antineoplastic Agents/therapeutic use , Myeloproliferative Disorders/drug therapy , Myeloproliferative Disorders/genetics , Oncogene Proteins, Fusion/genetics , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Receptor, Platelet-Derived Growth Factor beta/genetics , Aged , Benzamides , Child , Female , Humans , Imatinib Mesylate , In Situ Hybridization, Fluorescence , Infant , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...